|
Ceftriaxone sodium
Ceftriaxone sodium (Rocephin)
Ceftriaxone sodium
(sef-try-
AX-ohn)
Pregnancy Category: B
Rocephin
(Rx)
Classification:
Cephalosporin, third-generation
See Also:
See also
Anti-Infectives and
Cephalosporins
[.
]
Action/Kinetics:
t
1/2: Approximately 6-8 hr. Significantly protein bound.
Serum levels after 1 g IV: 151 mcg/mL. One-third to two-thirds excreted unchanged in the urine.
Uses:
(1) Lower respiratory tract infections due to
Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, H. parainfluenzae, Klebsiella pneumonia, Serratia marcescens, Escherichia coli, E. aerogenes, and
Proteus mirabilis. (2) Skin and skin structure infections due to
S. aureus, S. epidermidis, S. pyogenes, Viridins group streptococci,
E. coli, Enterobacter cloacae, K. oxytoca, K. pneumoniae, P. mirabilis, Pseudomonas aeruginosa, Morganella morganii, S. marcescens. Acinetobacter calcoaceticus, Bacgeroides fragilis, Peptostreptococcus species. UTIs (complicated and uncomplicted) due to
E. coli, P. mirabilis, P. vulgaris, M. morganii, and
K. pneumoniae. (3) Uncomplicated cervical/urethral and rectal gonorrhea due to
Neisseria gonorrhoeae, including penicillinase/non-penicillinase producing strains. (4) Pharyngeal gonorrhea due to non-penicillinase producing strains of
N. gonorrhoeae. PID due to
N. gonorrhoeae. (5) Bacterial septicemia due to
S. aureus, S. pneumoniae, E. coli, H. influenzae, and
K. pneumoniae. (6) Bone and joint infections due to
S. aureus, S. pneumoniae, E. coli, P. mirabilis, K. pneumoniae, and
Enterobacter species. (7) Intra-abdominal infections due to
E. coli, K. pneumoniae, B. fragilis, Clostridium species (most strains of
C. difficle are resistant),
Peptostreptococcus species. (8) Meningitis due to
H. influenzae, N. meningitidis, and
S. pneumoniae. (9) Single preoperative doses may decrease the incidence of postoperative infections following vaginal or abdominal hysterectomy or in coronary artery bypass surgery. (10) Pediatric otitis media.
Investigational: Neurologic complications, arthritis, and carditis associated with Lyme disease in clients refractory to penicillin G.
Additional Side Effects:
Increase in serum creatinine, presence of casts in the urine, alteration of PTs (rare).
How Supplied:
Injection: 1 g/50 mL, 2 g/50 mL;
Kit: 1 Gm-1%, 500 mg-1%;
Powder for injection: 250 mg, 500 mg, 1 g, 2 g, 10 g
Dosage
?IV, IM
General infections.
Adults, usual: 1-2 g/day in single or divided doses q 12 hr, not to exceed 4 g/day. Maintain therapy for 4-14 days, depending on the infection.
Pediatric: O
ther than meningitis: 50-75 mg/kg/day not to exceed total daily dose of 2 g given in divided doses q 12 hr.
Meningitis.
Pediatric: 100 mg/kg/day, not to exceed total daily dose of 4 g given once daily or in equally divided doses q 12 hr for 7-14 days.
Skin and skin structure infections.
Pediatric: 50-75 mg/kg once daily or in equally divided doses q 12 hr. Do no exceed a daily dose of 2 g.
Preoperative for prophylaxis of infection in surgery.
1 g 30-120 min prior to surgery.
Uncomplicated gonorrhea.
Adults, IM: 125 mg as a single dose plus doxycycline, 100 mg b.i.d. for 7 days or azithromycin, 1 g, as a single PO dose. Or, a single dose of 250 mg IM.
Disseminated gonococcal infection.
Adults: 1 g IM or IV q 24 hr.
Gonococcal meningitis or endocarditis.
Adults: 1-2 g IV q 12 hr for 10-14 days (meningitis) or 4 weeks (endocarditis).
Gonococcal conjunctivitis.
Adults and children over 20 kg: 1 g given as a single IM dose.
Haemophilus ducreyi infection.
250 mg IM as a single dose.
Acute pelvic inflammatory disease.
250 mg IM plus doxycycline or tetracycline.
Lyme disease in those refractory to Pencillin G.
IV: 2 g/day for 14-28 days.
Note: Dosage adjustment is not required for renal or hepatic impairment; however, monitor blood levels.
Acute bacterial otitis media.
IM: Single dose of 50 mg/kg, not to exceed 1 g. |
